Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Related Resources

Related Resources

Mint Medical and Agfa HealthCare announce seamless integration of mint Lesion and ORBIS RIS at RSNA 2018

Heidelberg, Bonn, GER - At this year’s Radiological Society of North America (RSNA) Annual Meeting 2018, Agfa HealthCare and Mint Medical will…

mint PI-RADS V2 report as the standard for communication with urologists - Interview with PD Dr. Röthke

Since the beginning of 2017, all PI-RADS v2 reads are exclusively performed with mint Lesion™ by PD Dr. Matthias Röthke, Chief Medical Officer at…

Assessment time halved: Importance of a good tumor response assessment tool in clinical site reads

The Clinical Research Imaging Core (CRIC) of the University of Wisconsin Carbone Cancer Center (UWCCC) recently published a poster at the AACI CRI…